US2017056408A1PendingUtilityA1

Medicament for treating peripheral neuropathies

Assignee: YU HSIAO LILYPriority: Jan 29, 2013Filed: Nov 10, 2016Published: Mar 2, 2017
Est. expiryJan 29, 2033(~6.5 yrs left)· nominal 20-yr term from priority
Inventors:Hsiao Lily Yu
A61K 45/06G01N 33/5091A61K 31/522C12Q 1/705A61K 9/0014
30
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (HSV), and then administering to the human the compound anti-HSV agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (Neurodermatitis, Prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, Alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, Crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, Parkinson's disease, anemia, cytopenia those among the diagnostic criteria.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising a compound:
 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one   or a pharmaceutically acceptable salt thereof, wherein the composition comprises an effective amount of the compound for treating a symptom of red swollen and inflammation on a skin of a human, caused by continued exposure to cold.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said salt comprises an acid salt. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein said salt comprises a phosphoric salt. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein said salt comprises a hydrochloride salt. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein said symptom occurs on a finger of said human. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein said symptom occurs on a toe of said human. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein said symptom further comprises itching and blisters on said skin of said human. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein said symptom occurs on a nose of said human. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein said symptom occurs on an ear of said human. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein said symptom further comprises erosions on said skin of said human. 
     
     
         11 . A pharmaceutical composition comprising a compound:
 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate   or a pharmaceutically acceptable salt thereof, wherein the composition comprises an effective amount of the compound for treating a symptom of red swollen and inflammation on a skin of a human, caused by continued exposure to cold.   
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein said salt comprises an acid salt. 
     
     
         13 . The pharmaceutical composition of  claim 11 , wherein said salt comprises a phosphoric salt. 
     
     
         14 . The pharmaceutical composition of  claim 11 , wherein said salt comprises a hydrochloride salt. 
     
     
         15 . The pharmaceutical composition of  claim 11 , wherein said symptom occurs on a finger of said human. 
     
     
         16 . The pharmaceutical composition of  claim 11 , wherein said symptom occurs on a toe of said human. 
     
     
         17 . The pharmaceutical composition of  claim 11 , wherein said symptom further comprises itching and blisters on said skin of said human. 
     
     
         18 . The pharmaceutical composition of  claim 11 , wherein said symptom occurs on a nose of said human. 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein said symptom occurs on an ear of said human. 
     
     
         20 . The pharmaceutical composition of  claim 11 , wherein said symptom further comprises erosions on said skin of said human.

Join the waitlist — get patent alerts

Track US2017056408A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.